Intra-Cellular’s depression drug goes 1 for 2 in Phase 3 studies BioPharma Dive
Intra-Cellular Therapies said Monday its experimental psychiatric drug had mixed results in two Phase 3 studies of patients with bipolar disorder, sending the …
Brought to you by Google News. Read the rest of the article here.